Investigator‐assessed adverse events (short‐term) N of participants with positive adverse events · people with acne scars
Injectable fillers showed no clear difference in investigator‐assessed adverse events (short‐term) N of participants… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Quality of life · people with acne scars
The review found no eligible studies for this question.
1 finding from 1 review
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed improvement in rosacea severity · Participants with rosacea
Azelaic acid leads to higher participant‐assessed improvement in rosacea severity Marked… compared with placebo (high certainty).
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
1 finding from 1 review
Physician‐assessed improvement in rosacea severity · Participants with rosacea
Azelaic acid leads to higher physician‐assessed improvement in rosacea severity compared with placebo (high certainty).
1 finding from 1 review
Assessment of erythema or telangiectasia · Participants with rosacea
1 finding from 1 review
Lesion count · Participants with rosacea
1 finding from 1 review
Time needed until improvement of the skin lesions · Participants with rosacea
1 finding from 1 review
Duration of remission ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
HRQOL DLQI and RosaQoL · Participants with rosacea
1 finding from 1 review
Participant‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
1 finding from 1 review
Participant‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Physician‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Assessment of erythema or telangiectasia ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Lesion count · Participants with rosacea
1 finding from 1 review
Time needed until improvement of the skin lesions · Participants with rosacea
1 finding from 1 review
Duration of remission ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
Metronidazole showed no clear difference in proportion of participants with adverse event compared with placebo (high certainty).
1 finding from 1 review